7 months ago
Polynovo shares surge on growth potential from US medicare overhaul
Investing.com-- Shares of Australian medical technology firm Polynovo Ltd (ASX:PNV) surged on Tuesday after the company said it could benefit from a proposed overhaul of U.S. Medicare reimbursement rules for outpatient wound care.
The Centers for Medicare & Medicaid Services (CMS) has proposed a flat reimbursement rate of $806 per square inch for skin substitutes, replacing the current model that rewards physicians with a percentage of product costs.
The change, aimed at cutting government spending that topped $10 billion in 2024, is expected to reduce incentives for high-cost products and promote clinically proven, cost-effective options.
PolyNovo said its NovoSorb wound-healing products would remain profitable under the new system, with margins intact and competitiveness enhanced.
Sydney-listed shares of the company advanced as much as 26.6% to A$1.665, but later pared gains to trade 6.8% higher at A$1.405 as of 04:15 GMT.
“Outpatient product application … is a significant potential growth area for PolyNovo’s products,” Acting CEO Robyn Elliott said.
"We are currently assessing the optimal commercial model for accessing this market opportunity," he added.
A final decision on the proposal is expected in November, with implementation slated for January 2026.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy.
Get the bottom line for PNV plus thousands of other stocks and find your next hidden gem with massive upside.
Click Subscribe #Polynovo #Medicare #HealthcareInvestment #StockMarket #WoundCare
0
0
0
0